D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...

In 2024, we established a strong foundation for what we expect will be a transformational year ahead for Compass,” said Thomas Schuetz, MD, ...

Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...

Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...

Compass Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and Alnylam Pharmaceuticals ALNY.

Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating ...

As of February 21, 2025, the average one-year price target for Compass Therapeutics is $11.35/share. The forecasts range from a low of $4.04 to a high of $33.60. The average price target ...

Highlights,Compass Therapeutics sees increased institutional engagement, with major firms expanding their holdings.,Research firms adjust ratings, reflecting varied perspectives on the company’s ...

Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its pipeline development programs and current cash position. The phenomenal ...